Allergan ( AGN), the maker of the wrinkle-zapper Botox, beat analysts' estimates and its own guidance for earnings in the fourth quarter.

The Irvine, Calif., company, which specializes in skin-care, eye-care and neurological products, earned $122 million, or 90 cents a share, in the last quarter of 2005, up from $112.5 million and 85 cents in the year-ago period.

Excluding charges, Allergan earned 91 cents a share, topping analysts' estimates of 89 cents a share and its November forecast of 88 cents to 89 cents a share.

Charges included those related to the termination of a supply agreement with Advanced Medical Optics ( EYE) and expenses incurred from efforts to streamline its research and development activities.

Net sales exceeded expectations as well, coming in at $594.9 million compared with Wall Street's target of $583.7 million. Pharmaceutical sales were up 11.3% from a year ago.

Sales of the Botox injection grew 12% to $227 million in the quarter, thanks in part to increased consumer acceptance of the drug and direct-to-consumer advertising, according to Allergan Chairman and CEO David Pyott. In addition, Allergan increased the price of Botox by 4% to $485 per vial of the drug, also known as botulinum toxin A.

Sales of its skin-care products disappointed, however, falling 8.5% because of fewer selling days in the quarter compared with a year earlier.

For 2006, Allergan projected earnings of $3.56 to $3.62 a share not including the impact of its acquisition of Inamed ( IMDC), a maker of cosmetic-surgery products, including breast implants. Its guidance does include a charge of 20 cents a share from stock-options expensing.

If you liked this article you might like

Nationwide Egg Recall Expanded

10 Toy Fads That Have Faded

Boomers Feel Recession Burden, Blame

KFC Franchisees Want 'Fried' to Be the Focus

Heavy Weights: More Expensive, Less Effective